Fri. Nov 15th, 2019

Global news

World Wide News

Stocks Alerts : Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO)

2 min read

Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), recently declared fiscal and operational results for the 3rd-quarter finished September 30, 2k19.

  • Q3 2k19 Revenues of $1.870M, a 13.00 percent sequential incline over Q2 2k19, and a 0.60 percent decline contrast to Q3 2k18
  • Q3 2k19 Gross Profit of $873,000.00, representing 46.70 percent of revenues, a sequential incline of 168.00 percent over Q2 2k19, and an 86.00 percent incline over Q3 2k18
  • Operating Loss in Q3 2k19 reduced by $1.250M to $2.80M, a sequential decline of 48.00 percent contrast to Q2 2k19 and a 31.00 percent decline contrast to Q3 2k18

Financial Results for the 3-months finished September 30, 2k19:

Revenue for the 3rd-quarter finished September 30, 2k19 was $1.870M, a 13.00 percent sequential incline over Q2 2k19 and a 0.60 percent decline from $1.880M in the 3rd-quarter finished September 30, 2k18.

Gross profit of $873,000.00, representing 46.70 percent of revenues, was recorded for the 3-months finished September 30, 2k19, a boost of 86.00 percent, or $405,000.00, a contrast to gross profit of $468,000.00 for the 3-months finished September 30, 2k18.

Operating loss for the 3-months finished September 30, 2k19 reduced by $1.250M to $2.80M, as contrast to a $4.50M operating loss for the 3-months finished September 30, 2k18.

Net loss attributable to holders of common stock reduced by $1.260M to $2.80M for the 3-months finished September 30, 2k19, as a contrast to $4.10M for the 3-months finished September 30, 2k18.

Our new B2B focus has allowed us to be more efficient with our use of cash, extending our runway of existing balance sheet resources.

As of September 30, 2k19, cash and cash equivalents totaled about $4.60M.

Non-GAAP billings for the 3-months finished September 30, 2k19 were $1.780M, a 20.00 percent decline from $2.20M in the 3-months finished September 30, 2k19. A reconciliation of GAAP to non-GAAP measures has been offered in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Financial Results for the 9.0-Months finished September 30, 2k19:

Revenue for the 9.0-months finished September 30, 2k19 was $5.760M, a 1.20 percent incline from $5.690M for the 9.0-months finished September 30, 2k18.

Gross profit of $1.760M was recorded for the 9.0-months finished September 30, 2k19, a boost of 14.00 percent, or $215,000.00, a contrast to gross profit of $1.540M for the 9.0-months finished September 30, 2k18.

Operating loss for the 9.0-months finished September 30, 2k19 increased by $762,000.00 to $13.50M, a contrast to a $12.80M operating loss for the 9.0-months finished September 30, 2k18.

Net loss attributable to holders of common stock increased by $743,000.00 to $13.560M for the 9.0-months finished September 30, 2k19, as a contrast to $12.820M for the 9.0-months finished September 30, 2k18.

Non-GAAP billings for the 9.0-months finished September 30, 2k19 were $6.340M, a 4.20 percent incline from $6.080M in the 9.0-months finished September 30, 2k19.

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.